Newsroom
Verve Therapeutics, Inc. Facing Securities Law Violations Lawsuits
By KlickAnalytics Data Insights | September 5, 2024 08:04PM ET
Key Points
- Multiple law firms are filing class action lawsuits against Verve Therapeutics, Inc. for alleged securities law violations
- Investors who suffered losses on their VERV investments are urged to contact legal firms for potential recovery
- The lawsuits are based on violations of 10(b) and 20(a) of the Securities Exchange Act of 1934
- Shareholders of Verve Therapeutics are being notified of upcoming deadlines to participate in the lawsuits
- The lawsuits cover the period between August 9, 2022, and April 1, 2024
Several law firms across the United States have filed class action lawsuits against Verve Therapeutics, Inc., alleging violations of securities laws. Investors who experienced losses on their Verve Therapeutics, Inc. (NASDAQ: VERV) investments are being advised to reach out to these legal firms for potential recovery under federal securities regulations.
The lawsuits against Verve Therapeutics, Inc. are focused on violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 regulated by the U.S. Securities and Exchange Commission. These allegations have prompted legal actions by firms such as Levi & Korsinsky, The Schall Law Firm, Rosen Law Firm, Pomerantz Law Firm, and the Gross Law Firm among others.
Investors who were affected by losses related to Verve Therapeutics, Inc. are being reminded of important deadlines to participate in the class action lawsuits initiated by various law firms. The Class Period covered by these lawsuits spans from August 9, 2022, to April 1, 2024, during which investors allegedly suffered financial harm due to the company's actions.
With multiple legal firms actively pursuing class action lawsuits against Verve Therapeutics, Inc., shareholders are encouraged to seek legal counsel and explore their options for potential recovery. The allegations of securities law violations have prompted a series of legal actions aimed at holding the company accountable for its actions. Investors should stay informed and take proactive steps to protect their rights in these legal proceedings.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with